Who’s most likely to develop Alzheimer’s and why? South Florida researchers recruit diverse groups for studies.

A criticism of the new Alzheimer’s drug, Aduhelm, is that only 0.6% of participants in the trials were Black, and 3% were Hispanic. In Nature, Lisa Barnes, a cognitive neuropsychologist, wrote that without studies that resemble the actual population of people living with Alzheimer’s, scientists will never reach a complete understanding of racial disparities of the disease.